- Home
- FTW vs INBX Comparison
FTW vs INBX Comparison
Compare FTW & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$74.96
Company Overview
Basic Information| Metric | FTW | INBX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.2M | 1.1B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FTW | INBX |
|---|---|---|
| Price | $10.55 | $74.96 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 197.5K |
| Earning Date | N/A | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $10.81 |
| 52 Week High | N/A | $94.57 |
Technical Indicators
Market Signals| Indicator | FTW | INBX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.30 |
| Support Level | N/A | $70.60 |
| Resistance Level | N/A | $82.16 |
| Average True Range (ATR) | 0.00 | 4.83 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 0.00 | 42.79 |
Price Performance
Historical Comparison FTW
INBX
About FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares
EQV Ventures Acquisition Corp is a blank check company.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.